Loading...

Margaret Tempero, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Phone415-353-7528
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of NebraskaM.D.1977School of Medicine
    Collapse Awards and Honors
    UCSF2012  - PresRombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science
    UCSF2000  - 2012Doris and Don Fisher Distinguished Professor in Clinical Research
    Journal Nat'l Comprehensive Cancer Network2014  - PresEditor-In-Chief

    Collapse Overview 
    Collapse Overview
    Dr. Tempero is Director, UCSF Pancreas Center and Leader, Pancreas Cancer Program. Her research career has focused on pancreatic ductal adenocarcinoma especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Her group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials. Currently her group is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation.

    Dr. Tempero directed the first GI SPORE devoted to pancreatic cancer when she was on the faculty of the University of Nebraska and subsequently led the NCI funded U54 Molecular Target Assessment Team at UCSF. She also organized the first Pancreas Cancer Think Tank in 1999 and co-led the NCI sponsored Progress Review Group on Pancreatic Cancer in 2000. She has served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. She also serves on the Pancreatic Cancer Task Force for the NCI intergroup and recently co-organized the State of the Science meeting on pancreatic cancer at the NCI.

    Dr. Tempero also has extensive experience in scientific review and administration, training and oversight. She co-directed the AACR/ASCO Methods in Clinical Cancer Research in Vail for 3 years and spent 9 years of service teaching this course and similar courses in Europe and Australia. She was founding Chair of the NCI Clinical Oncology Study Section (CONC) and served as a member and Chair (2-year term) of the NCI Board of Scientific Counselors Subcommittee A. She is on the External Advisory Boards of the Pancreas SPORE at MDACC and the GI SPOREs at the University of Arizona and Northwestern. She is, or has been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC. She has held many appointments at AACR and ASCO and has served as a member of the ASCO Board of Directors and as ASCO President in 2004. She recently served as a member of the Oncology Drug Advisory Committee for the FDA. She served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, Chief Emeritus of the Division of Medical Oncology at UCSF (2000 – 2007) and Deputy Director and Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) from 2000 to 2012.


    Collapse Research 
    Collapse Research Activities and Funding
    Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma
    NIH/NCI R21CA184429Sep 15, 2014 - Aug 31, 2016
    Role: Principal Investigator
    Mechanism-Based Evaluations of ErbB-Targeted Agents
    NIH/NCI U54CA090788Sep 26, 2001 - Dec 31, 2008
    Role: Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA082103Aug 5, 1999 - May 31, 2018
    Role: Co-Investigator
    SPORE IN GASTOINTESTINAL CANCER
    NIH/NCI P50CA072712Sep 1, 1997 - Jan 31, 2005
    Role: Co-Principal Investigator
    DEFINING TOXICITY AND BENEFIT FOR RADIOIMMUNOTHERAPY
    NIH/NCI U01CA058272Sep 30, 1993 - Sep 29, 2000
    Role: Principal Investigator
    Fred & Pamela Buffett Cancer Center Support Grant
    NIH/NCI P30CA036727Jul 1, 1984 - Jul 31, 2021
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tempero M. I'm Conflicted. Are You? J Natl Compr Canc Netw. 2018 Nov; 16(11):1273. PMID: 30442729.
      View in: PubMed
    2. Tempero M. One Size Fits All? Really? J Natl Compr Canc Netw. 2018 Oct; 16(10):1161. PMID: 30323084.
      View in: PubMed
    3. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2018 Sep 28. PMID: 30267352.
      View in: PubMed
    4. Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol. 2018 Sep 11. PMID: 30211728.
      View in: PubMed
    5. Tempero M. Getting What You Pay For: Finding Value in Cancer Care. J Natl Compr Canc Netw. 2018 Sep; 16(9):1031. PMID: 30181413.
      View in: PubMed
    6. Tempero M. Notes From the Other Side. J Natl Compr Canc Netw. 2018 Aug; 16(8):921-922. PMID: 30099366.
      View in: PubMed
    7. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 Jul 31; 1-10. PMID: 30063366.
      View in: PubMed
    8. Tempero M. Genomic Medicine Takes the Stage, Again! J Natl Compr Canc Netw. 2018 Jul; 16(7):795. PMID: 30006420.
      View in: PubMed
    9. Tempero M. Movin' On Up! J Natl Compr Canc Netw. 2018 Jun; 16(6):675. PMID: 29891517.
      View in: PubMed
    10. Tempero M. Getting Into the Weeds. J Natl Compr Canc Netw. 2018 May; 16(5):457. PMID: 29752317.
      View in: PubMed
    11. Tempero M. Standing Together or Alone. J Natl Compr Canc Netw. 2018 Apr; 16(4):341. PMID: 29632051.
      View in: PubMed
    12. Tempero M. Molecular Diagnostics: Another Battle Brewing. J Natl Compr Canc Netw. 2018 Mar; 16(3):225. PMID: 29523658.
      View in: PubMed
    13. Tempero M. Extending Our Reach-Will Telemedicine Get Us There? J Natl Compr Canc Netw. 2018 Feb; 16(2):107. PMID: 29439170.
      View in: PubMed
    14. Tempero M. Revisiting New Year's Resolutions. J Natl Compr Canc Netw. 2018 Jan; 16(1):1. PMID: 29295874.
      View in: PubMed
    15. Tempero M. It's About Time! J Natl Compr Canc Netw. 2017 Dec; 15(12):1443. PMID: 29223979.
      View in: PubMed
    16. Tempero MA. Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Cancer J. 2017 Nov/Dec; 23(6):309. PMID: 29189324.
      View in: PubMed
    17. Tempero M. Who's Watching the Kids? J Natl Compr Canc Netw. 2017 Nov; 15(11):1289. PMID: 29118220.
      View in: PubMed
    18. Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017 Nov 17; 8(58):97769-97786. PMID: 29228650.
      View in: PubMed
    19. Doherty GJ, Tempero M, Corrie PG. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018 Jan; 14(1):13-22. PMID: 29235360.
      View in: PubMed
    20. Tempero M. Serving "a la CAR-T": Value-Based Pricing and Gene Therapy. J Natl Compr Canc Netw. 2017 Oct; 15(10):1179. PMID: 28982741.
      View in: PubMed
    21. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 Dec; 22(12):1427-e129. PMID: 28935773.
      View in: PubMed
    22. Tempero M. Your Genes: Getting the Best Fit. J Natl Compr Canc Netw. 2017 Sep; 15(9):1083. PMID: 28874592.
      View in: PubMed
    23. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Aug; 15(8):1028-1061. PMID: 28784865.
      View in: PubMed
    24. Tempero M. When It's Really Good, We Know It! J Natl Compr Canc Netw. 2017 Aug; 15(8):973. PMID: 28784856.
      View in: PubMed
    25. Tempero M. Reducing the Cost of Cancer Care: When Less Is More. J Natl Compr Canc Netw. 2017 Jul; 15(7):853. PMID: 28687571.
      View in: PubMed
    26. Tempero M. Getting Practical About Recertification. J Natl Compr Canc Netw. 2017 Jun; 15(6):753. PMID: 28596253.
      View in: PubMed
    27. Tempero M. Hospice: Angels at Work. J Natl Compr Canc Netw. 2017 05; 15(5):549. PMID: 28476733.
      View in: PubMed
    28. Tempero M. Active Systemic Treatment of Pancreatic Cancer. J Natl Compr Canc Netw. 2017 May; 15(5S):723-725. PMID: 28515255.
      View in: PubMed
    29. Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4). PMID: 28376157.
      View in: PubMed
    30. Tempero M. Politics as Usual-Not! J Natl Compr Canc Netw. 2017 04; 15(4):425. PMID: 28404753.
      View in: PubMed
    31. Tempero M. Saying Yes. J Natl Compr Canc Netw. 2017 03; 15(3):277. PMID: 28275029.
      View in: PubMed
    32. Tempero M. Mad About MACRA. J Natl Compr Canc Netw. 2017 02; 15(2):137. PMID: 28188184.
      View in: PubMed
    33. Tempero M. New Year's Resolutions. J Natl Compr Canc Netw. 2017 01; 15(1):1. PMID: 28040714.
      View in: PubMed
    34. van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. Assessing Researcher Needs for a Virtual Biobank. Biopreserv Biobank. 2017 Jun; 15(3):203-210. PMID: 27929677.
      View in: PubMed
    35. Tempero M. An Oncologist's Letter to Santa. J Natl Compr Canc Netw. 2016 12; 14(12):1491. PMID: 27956532.
      View in: PubMed
    36. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA. Hypermutation In Pancreatic Cancer. Gastroenterology. 2017 01; 152(1):68-74.e2. PMID: 27856273.
      View in: PubMed
    37. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 Nov; 45(10):1394-1400. PMID: 27171514.
      View in: PubMed
    38. Tempero M. My Knee Hurts! J Natl Compr Canc Netw. 2016 11; 14(11):1335. PMID: 27799504.
      View in: PubMed
    39. Tempero M. Crossing the Line. J Natl Compr Canc Netw. 2016 10; 14(10):1191. PMID: 27697973.
      View in: PubMed
    40. Tempero M. Hillary and Donald, Our Patients Are Watching. J Natl Compr Canc Netw. 2016 09; 14(9):1047. PMID: 27587617.
      View in: PubMed
    41. Tempero M. I'll Have Another Shot, Please! J Natl Compr Canc Netw. 2016 08; 14(8):929. PMID: 27496107.
      View in: PubMed
    42. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596. PMID: 27444658.
      View in: PubMed
    43. Tempero M. The Greatest Show on Earth! J Natl Compr Canc Netw. 2016 07; 14(7):813. PMID: 27407120.
      View in: PubMed
    44. Tempero M. Did the IRB Approve This? J Natl Compr Canc Netw. 2016 06; 14(6):699. PMID: 27283161.
      View in: PubMed
    45. Tempero M. Closely Guarded Secrets. J Natl Compr Canc Netw. 2016 05; 14(5):487. PMID: 27160226.
      View in: PubMed
    46. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016 04 21; 2:16022. PMID: 27158978.
      View in: PubMed
    47. Tempero M. Letting Nature Loose. J Natl Compr Canc Netw. 2016 Apr; 14(4):367. PMID: 27059185.
      View in: PubMed
    48. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5. PMID: 26390428.
      View in: PubMed
    49. Tempero M. Promising the Moon! J Natl Compr Canc Netw. 2016 Mar; 14(3):237. PMID: 26957609.
      View in: PubMed
    50. Tempero M. Put Us Out of Business--Please! J Natl Compr Canc Netw. 2016 Feb; 14(2):123. PMID: 26850482.
      View in: PubMed
    51. Tempero M. Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. J Oncol Pract. 2016 Jan; 12(1):29-30. PMID: 26759462.
      View in: PubMed
    52. Tempero M. Bringing Biosimilars to the Clinic: What's the Fuss? J Natl Compr Canc Netw. 2016 Jan; 14(1):1. PMID: 26733549.
      View in: PubMed
    53. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 2016 Mar; 6(3):270-85. PMID: 26715645; PMCID: PMC4783268.
    54. Tempero M. Paying Less for High-Value Care--Are You Kidding Me? J Natl Compr Canc Netw. 2015 Dec; 13(12):1453. PMID: 26656513.
      View in: PubMed
    55. Tempero M. At Last: Getting Paid to Think! J Natl Compr Canc Netw. 2015 Nov; 13(11):1297. PMID: 26553759.
      View in: PubMed
    56. Tempero M. Putting an End to It! J Natl Compr Canc Netw. 2015 Oct; 13(10):1167. PMID: 26483055.
      View in: PubMed
    57. Tempero M. Crossing Over. J Natl Compr Canc Netw. 2015 Sep; 13(9):1053. PMID: 26358787.
      View in: PubMed
    58. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8. PMID: 26251290; PMCID: PMC4703532 [Available on 01/01/17].
    59. Tempero M. Move It! J Natl Compr Canc Netw. 2015 Aug; 13(8):939. PMID: 26285237.
      View in: PubMed
    60. Tempero M. Express Scripts? Really? J Natl Compr Canc Netw. 2015 Jul; 13(7):827. PMID: 26150575.
      View in: PubMed
    61. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. PMID: 26109333; PMCID: PMC4592417.
    62. Tempero M. Improving Access to Drugs--Big Pharma Comes to the Table. J Natl Compr Canc Netw. 2015 Jun; 13(6):703. PMID: 26085384.
      View in: PubMed
    63. Tempero MA. Multidisciplinary management of pancreatic cancer. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):700-2. PMID: 25995435.
      View in: PubMed
    64. Tempero M. Reducing costs by changing behavior-really? J Natl Compr Canc Netw. 2015 May; 13(5):499. PMID: 25964633.
      View in: PubMed
    65. Tempero M. Turf war over diagnostic testing. J Natl Compr Canc Netw. 2015 Apr; 13(4):375. PMID: 25870372.
      View in: PubMed
    66. Tempero M. Putting precision medicine on the national agenda. J Natl Compr Canc Netw. 2015 Mar; 13(3):251. PMID: 25736000.
      View in: PubMed
    67. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015 Feb 26; 518(7540):495-501. PMID: 25719666.
      View in: PubMed
    68. Tempero M. All bundled up! J Natl Compr Canc Netw. 2015 Feb; 13(2):121. PMID: 25691601.
      View in: PubMed
    69. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20; 33(6):654-6. PMID: 25605844; PMCID: PMC4881372.
    70. Tempero M. Meet the New JNCCN! J Natl Compr Canc Netw. 2015 Jan; 13(1):1. PMID: 25583762.
      View in: PubMed
    71. Tempero M. Happy anniversary! J Natl Compr Canc Netw. 2014 Dec; 12(12):1653. PMID: 25505204.
      View in: PubMed
    72. Tempero M. Bringing science to clinical practice. J Natl Compr Canc Netw. 2014 Nov; 12(11):1495. PMID: 25361794.
      View in: PubMed
    73. Tempero M. Cancer screening: when is the juice worth the squeeze? J Natl Compr Canc Netw. 2014 Oct; 12(10):1359. PMID: 25313175.
      View in: PubMed
    74. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70. PMID: 25199993.
      View in: PubMed
    75. Tempero M. Getting what you pay for: finding value in cancer care. J Natl Compr Canc Netw. 2014 Sep; 12(9):1199. PMID: 25190688.
      View in: PubMed
    76. Tempero M. Incentive-based oncology: unintended consequences? J Natl Compr Canc Netw. 2014 Aug; 12(8):1069. PMID: 25099438.
      View in: PubMed
    77. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93. PMID: 25099441.
      View in: PubMed
    78. Tempero M. A publicly funded clinical trials network: do we need it? J Natl Compr Canc Netw. 2014 Jul; 12(7):953. PMID: 24994914.
      View in: PubMed
    79. Tempero M. Embracing team-based oncology care. J Natl Compr Canc Netw. 2014 Jun; 12(6):845. PMID: 24925194.
      View in: PubMed
    80. Tempero M. Managing the fruits of our success. J Natl Compr Canc Netw. 2014 May; 12(5):603. PMID: 24812128.
      View in: PubMed
    81. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9. PMID: 24622062.
      View in: PubMed
    82. Tempero M. The changing face of community practice: the new normal. J Natl Compr Canc Netw. 2014 Apr; 12(4):449. PMID: 24717562.
      View in: PubMed
    83. Tempero M. JNCCN going forward. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):301. PMID: 24616533.
      View in: PubMed
    84. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. PMID: 24022191; PMCID: PMC3790192.
    85. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5. PMID: 23880820; PMCID: PMC3749576.
    86. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013 Jun; 144(6):1316-26. PMID: 23622141.
      View in: PubMed
    87. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10; 31(17):2189-204. PMID: 23669224.
      View in: PubMed
    88. Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res. 2013 Feb 01; 19(3):538-40. PMID: 23344262.
      View in: PubMed
    89. Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):653-64. PMID: 23187854.
      View in: PubMed
    90. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15; 491(7424):399-405. PMID: 23103869; PMCID: PMC3530898.
    91. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. PMID: 21552099.
      View in: PubMed
    92. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81. PMID: 23053263.
      View in: PubMed
    93. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):703-13. PMID: 22679115; PMCID: PMC3807091.
    94. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3. PMID: 21460848; PMCID: PMC3755490.
    95. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011 Jul; 22(7):1500-6. PMID: 21199884.
      View in: PubMed
    96. Collisson E, Tempero M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res. 2011 Jan 15; 17(2):203-5. PMID: 21106729.
      View in: PubMed
    97. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010 Sep; 8(9):972-1017. PMID: 20876541; PMCID: PMC3135380.
    98. International network of cancer genome projects. Nature. 2010 Apr 15; 464(7291):993-8. PMID: 20393554.
      View in: PubMed
    99. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. PMID: 20130876.
      View in: PubMed
    100. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20; 27(33):5660-9. PMID: 19858397.
      View in: PubMed
    101. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12. PMID: 19858396; PMCID: PMC2792952.
    102. Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5. PMID: 19041649.
      View in: PubMed
    103. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. PMID: 18815548.
      View in: PubMed
    104. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. PMID: 18379729.
      View in: PubMed
    105. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. PMID: 18181045.
      View in: PubMed
    106. Tempero MA. How I treat pancreatic ductal adenocarcinoma. J Oncol Pract. 2008 Jan; 4(1):46-7. PMID: 20859443; PMCID: PMC2793930.
    107. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Nov; 5(10):998-1033. PMID: 18053426.
      View in: PubMed
    108. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007 Jun; 18 Suppl 7:vii1-vii10. PMID: 17600091.
      View in: PubMed
    109. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):809-16. PMID: 17363191.
      View in: PubMed
    110. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33. PMID: 17655039.
      View in: PubMed
    111. Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007 Feb; 25(1):85-94. PMID: 16957834.
      View in: PubMed
    112. Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res. 2006 Jan 01; 66(1):14-7. PMID: 16397208.
      View in: PubMed
    113. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. PMID: 16344320.
      View in: PubMed
    114. Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53. PMID: 16183478.
      View in: PubMed
    115. Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):598-626. PMID: 16194453.
      View in: PubMed
    116. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36. PMID: 16194454.
      View in: PubMed
    117. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. PMID: 15999098; PMCID: PMC2361548.
    118. Tempero MA. Clinical oncology 2004: the president's report. J Clin Oncol. 2004 Nov 15; 22(22):4437-41. PMID: 15542796.
      View in: PubMed
    119. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003 Sep 15; 21(18):3402-8. PMID: 12885837.
      View in: PubMed
    120. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34(2-3):107-16. PMID: 15361643.
      View in: PubMed
    121. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002 Sep; 2(8):774-9. PMID: 12243499.
      View in: PubMed
    122. Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med. 2002 Jul; 43(7):957-67. PMID: 12097469.
      View in: PubMed
    123. Ko AH, Tempero MA. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12. PMID: 11937010.
      View in: PubMed
    124. Augustine SC, Norenberg JP, Colcher DM, Vose JM, Gobar LS, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero MA. Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc (Wash). 2002 Jan-Feb; 42(1):93-100. PMID: 11833524.
      View in: PubMed
    125. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001 Jun 15; 61(12):4923-32. PMID: 11406572.
      View in: PubMed
    126. Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, Dukat VJ, Hohenstein MA, Gobar LS, Vose JM. Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001 Jun; 42(6):907-15. PMID: 11390555.
      View in: PubMed
    127. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999 Dec; 117(6):1464-84. PMID: 10579989.
      View in: PubMed
    128. Brand RE, Tempero MA. Pancreatic cancer. Curr Opin Oncol. 1998 Jul; 10(4):362-6. PMID: 9702405.
      View in: PubMed
    129. Tempero MA, Brand R. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1998 May 01; 82(9):1800-1. PMID: 9576306.
      View in: PubMed
    130. Habbe TG, McCowan TC, Goertzen TC, Leveen RF, Culp WC, Tempero MA. Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy. J Vasc Interv Radiol. 1998 Mar-Apr; 9(2):233-9. PMID: 9540905.
      View in: PubMed
    131. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997 Apr; 38(4):512-6. PMID: 9098192.
      View in: PubMed
    132. Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK. Radiolabeled iododeoxyuridine: safety evaluation. J Nucl Med. 1996 Apr; 37(4 Suppl):13S-16S. PMID: 8676196.
      View in: PubMed
    133. Sivinski CL, Lindner DJ, Borden EC, Tempero MA. Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons. J Immunother Emphasis Tumor Immunol. 1995 Oct; 18(3):156-65. PMID: 8770771.
      View in: PubMed
    134. Kessinger A, Bishop MR, Anderson JR, Armitage JO, Bierman PJ, Reed EC, Tarantolo S, Tempero MA, Vose JM, Warkentin PI. Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization. J Hematother. 1995 Apr; 4(2):81-4. PMID: 7543352.
      View in: PubMed
    135. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev. 1994 Mar; 3(2):155-60. PMID: 8049637.
      View in: PubMed
    136. Haga Y, Sivinski CL, Woo D, Tempero MA. Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. Int J Pancreatol. 1994 Feb; 15(1):43-50. PMID: 8195641.
      View in: PubMed
    137. Hirota M, Pour PM, Tempero MA, Chaney WG. Purification and analysis of glycoproteins bearing blood group-A determinants from hamster pancreatic ductal adenocarcinomas. Carcinogenesis. 1992 Oct; 13(10):1829-33. PMID: 1385001.
      View in: PubMed
    138. Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, Quaife MA, Sharp JG. Quantitation of metastatic tumor burden from human colon tumor xenografts using radiolabelled monoclonal antibody 17-A fragments. Tumour Biol. 1992; 13(4):195-206. PMID: 1411138.
      View in: PubMed
    139. Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, Pour P. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma. Int J Pancreatol. 1991; 9:125-34. PMID: 1744438.
      View in: PubMed
    140. Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J Clin Oncol. 1990 Dec; 8(12):2019-26. PMID: 2121912.
      View in: PubMed
    141. Tempero MA. Advances in the medical management of advanced gastrointestinal cancers. Curr Opin Oncol. 1990 Aug; 2(4):747-53. PMID: 2095882.
      View in: PubMed
    142. Tempero MA, Nishioka K, Knott K, Zetterman RK. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res. 1989 Nov 01; 49(21):5793-7. PMID: 2507137.
      View in: PubMed
    143. Takiyama Y, Tempero MA, Takasaki H, Onda M, Tsuchiya R, Büchler M, Ness M, Colcher D, Schlom J, Pour PM. Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases. Hum Pathol. 1989 Sep; 20(9):832-8. PMID: 2673979.
      View in: PubMed
    144. Takasaki H, Tempero MA, Uchida E, Büchler M, Ness MJ, Burnett DA, Metzgar RS, Colcher D, Schlom J, Pour PM. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. Int J Cancer. 1988 Nov 15; 42(5):681-6. PMID: 3053465.
      View in: PubMed
    145. Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA, Steplewski Z. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res. 1988 Oct 01; 48(19):5422-6. PMID: 3166398.
      View in: PubMed
    146. Ness MJ, Pour PM, Tempero MA, Linder J. Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. Mod Pathol. 1988 Jul; 1(4):279-83. PMID: 2467286.
      View in: PubMed
    147. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 1988 Mar 15; 48(6):1435-8. PMID: 3162196.
      View in: PubMed
    148. Tempero MA, Zetterman RK. Effects of sodium cholate on experimental carcinogenesis and cell proliferation in an excluded colonic segment. J Surg Oncol. 1987 Dec; 36(4):253-8. PMID: 3695530.
      View in: PubMed
    149. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987 Oct 15; 47(20):5501-3. PMID: 3308077.
      View in: PubMed
    150. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue. Int J Pancreatol. 1987 Oct-Dec; 2(5-6):349-60. PMID: 3320227.
      View in: PubMed
    151. Uchida E, Tempero MA, Burnett DA, Steplewski Z, Pour PM. Correlative studies on antigenicity of pancreatic cancer and blood group types. Cancer Detect Prev Suppl. 1987; 1:145-8. PMID: 3319143.
      View in: PubMed
    152. Petrie HT, Klassen LW, Tempero MA, Kay HD. In vitro regulation of human lymphocyte proliferation by selenium. Biol Trace Elem Res. 1986 Dec; 11(1):129-46. PMID: 24254509.
      View in: PubMed
    153. Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma. 1986 Jul; 5 Suppl 1:S133-8. PMID: 3744378.
      View in: PubMed
    154. Tempero M. Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review. Dig Dis. 1986; 4(1):49-56. PMID: 3545561.
      View in: PubMed